



Summary Prescription Drug Costs Report

Small Group & Individual Markets, Plan Year 2023

09/06/2024

Table of Contents

Cover Letter	3
Reporting process	3
Requested data elements	3
Data limitations	4
Small Group Market – Summary Prescription Drug Costs Reporting	5
Part 1: Most Frequently Prescribed Drugs	5
Part 2: Most Costly Prescription Drugs as a Portion of Total Annual Expenditures	6
Part 3: Prescription Drugs that have Caused the Greatest Increase in Total Spending	7
Part 4: Inquiry & Response Items	8
Individual Market – Summary Prescription Drug Costs Reporting	9
Part 1: Most Frequently Prescribed Drugs	9
Part 2: Most Costly Prescription Drugs as a Portion of Total Annual Expenditures	10
Part 3: Prescription Drugs that have Caused the Greatest Increase in Total Spending	11
Part 4: Inquiry & Response Items	12
Prescription Drug Data Collection Templates.....	13
D3: Top 50 Most Frequently Prescribed Drugs	13
D4: Top 50 Most Costly Prescription Drugs.....	14
D5: Top 50 Prescription Drugs by Spending Increase	15
Prescription Drug Cost Supplemental Form	16

Prescription Drug Costs

In 2019, Minnesota amended Minn. Stat. Chapter 62K.07 to increase visibility into the cost of providing prescription drug benefits in individual and small group market health plans. Each carrier offering a prescription drug benefit in its individual or small group health plans is required to include certain prescription drug data in the applicable rate filing. Commerce, in consultation with Health, is required to release a summary of the data reported.

Reporting process

The Department provided instructions and a template for reporting data. Beginning in 2023, the department decided to reduce duplicative work by the individual and small group carriers by using the reporting and/or underlying data from the Consolidated Appropriations Act's (CAA) Prescription Drug Data Collections (RxDC). Carriers were encouraged to limit the data provided in the RxDC templates to only reflect data for Minnesota and the applicable market segment. Each health carrier was required to submit their prescription drug cost reporting information to the Department via SERFF within the applicable rate filing or binder by June 3, 2024.

The Department received reports from all eight carriers filing to offer plans in the small group market and from all five carriers filing to offer plans in the individual market.

The data in the attached summary reports is drawn from the information as submitted by the carriers. Within each summary report, ranking is determined based on the aggregate sum of reports of a specific Rx Drug Code.

Requested data elements

The following data was requested from each health carrier filing to offer individual or small group health plans in 2024:

1. The 50 most frequently prescribed drugs in 2023 (RxDC D3).
2. The 50 most costly prescribed drugs as a portion of total annual expenditures in 2023 (RxDC D4).
3. The 50 prescription drugs that caused the greatest increase in total spending in 2023 (RxDC D5).
4. The projected impact of the cost of prescription drugs on 2025 premium rates.
5. Whether any health plan offered requires enrollees to pay cost-sharing on covered prescription drugs in an amount greater than the health plan would pay for the drug absent the applicable cost-sharing and after any rebate amount.
6. Whether third-party payments, such as drug manufacturer discounts or coupons that cover all or a portion of the enrollee's cost-sharing, apply towards the enrollee's cost-sharing obligations.

A copy of the reporting templates are included beginning on page 13.

Data limitations

- The Department has reported data as submitted by the carriers and cannot guarantee its accuracy.
- Certain prescription drug names may appear multiple times within the same summary report due to differences in manufacturer, form, dosage, packaging, etc. by RxDC code.
- While the Department provided instruction, methods for ranking prescription drugs may have varied by carrier due to interpretation.
- The data in the summary reports has not been independently audited.

Small Group Market - Summary Prescription Drug Costs Reporting - Part 1

Top 25 Most Frequently Prescribed Drugs in Plan Year 2023

Rank	Drug Code (RxDC)	Drug Name	Total Number of Prescriptions
1	R19913020101001	semaglutide [Ozempic]	12,767
2	R00007250201001	amphetamine dextroamphetamine [Adderall]	12,481
3	R00004350101004	albuterol [Ventolin]	11,931
4	R07008100101001	lisdexamfetamine [Vyvanse]	7,789
5	R15456530101001	empagliflozin [Jardiance]	6,050
6	R03273610101001	adalimumab [Humira]	5,688
7	R15512910101001	dulaglutide [Trulicity]	5,093
8	R00411260201001	fluticasone salmeterol [Advair]	5,086
9	R13644300101001	apixaban [Eliquis]	4,608
10	R11141950101001	rivaroxaban [Xarelto]	2,952
11	R00514280101002	insulin aspart human [NovoLog]	2,722
12	R00411260101005	fluticasone [Flovent]	2,633
13	R00069010101003	methylphenidate [Concerta]	2,551
14	R25878920201002	nirmatrelvir ritonavir [Paxlovid 5-Day]	2,457
15	R02747830101002	insulin glargine [Lantus]	2,408
16	R26017230101001	tirzepatide [Mounjaro]	2,406
17	R18763760101001	dupilumab [Dupixent]	2,332
18	R00198310201001	budesonide formoterol [Symbicort]	2,227
19	R02747830101003	insulin glargine [Semglee]	2,053
20	R00105820101005	levothyroxine [Synthroid]	2,036
21	R19913020101003	semaglutide [Wegovy]	1,770
22	R02145550101001	etanercept [Enbrel]	1,746
23	R19868210101001	varicella zoster virus glycoprotein E [Shingrix]	1,587
24	R00411260202001	fluticasone vilanterol [Breo]	1,575
25	R14885640101001	dapagliflozin [Farxiga]	1,499

Small Group Market - Summary Prescription Drug Costs Reporting - Part 2

**Most Costly Prescription Drugs as a Portion of
Total Annual Expenditures in Plan Year 2023**

Rank	Drug Code (RxDC)	Drug Name	Aggregate Annual Cost of Drug
1	R03273610101001	adalimumab [Humira]	\$26,528,941
2	R08470830101001	ustekinumab [Stelara]	\$12,223,774
3	R19913020101001	semaglutide [Ozempic]	\$9,130,123
4	R21660400101001	risankizumab [Skyrizi]	\$8,084,565
5	R02145550101001	etanercept [Enbrel]	\$7,089,655
6	R18763760101001	dupilumab [Dupixent]	\$6,586,613
7	R22569510301001	elexacaftor ivacaftor tezacaftor [Trikafta]	\$6,283,810
8	R15512910101001	dulaglutide [Trulicity]	\$4,454,631
9	R15456530101001	empagliflozin [Jardiance]	\$3,861,382
10	R03423690101001	lenalidomide [Revlimid]	\$3,190,723
11	R13644300101001	apixaban [Eliquis]	\$3,113,610
12	R15997880101001	secukinumab [Cosentyx]	\$3,059,957
13	R19996600302001	bictegravir emtricitabine tenofovir alafenamide [Biktarvy]	\$2,928,307
14	R21960920101001	upadacitinib [Rinvoq]	\$2,835,935
15	R07008100101001	lisdexamfetamine [Vyvanse]	\$2,526,604
16	R19913020101003	semaglutide [Wegovy]	\$2,172,014
17	R17450990101001	ixekizumab [Taltz]	\$2,101,706
18	R26017230101001	tirzepatide [Mounjaro]	\$2,043,001
19	R11141950101001	rivaroxaban [Xarelto]	\$2,029,159
20	R17202590101001	asfotase alfa [Strensiq]	\$1,960,505
21	R19285880101001	guselkumab [Tremfya]	\$1,947,315
22	R06143910101001	abatacept [Orencia]	\$1,728,371
23	R03582570101001	tolvaptan [Jynarque]	\$1,711,229
24	R02762370201001	emtricitabine tenofovir alafenamide [Descovy]	\$1,705,409
25	R14927270101001	apremilast [Otezla]	\$1,605,505

Small Group Market - Summary Prescription Drug Costs Reporting - Part 3

**Prescription Drugs that have Caused the
Greatest Increase in Total Spending in Plan Year 2023**

Rank	Drug Code (RxDC)	Drug Name	Aggregate Increase in Annual Spending
1	R19913020101001	semaglutide [Ozempic]	\$5,069,932
2	R21660400101001	risankizumab [Skyrizi]	\$3,078,069
3	R03273610101001	adalimumab [Humira]	\$2,720,467
4	R18763760101001	dupilumab [Dupixent]	\$2,629,523
5	R19913020101003	semaglutide [Wegovy]	\$1,878,427
6	R08470830101001	ustekinumab [Stelara]	\$1,868,454
7	R15456530101001	empagliflozin [Jardiance]	\$1,635,954
8	R02145550101001	etanercept [Enbrel]	\$1,375,999
9	R21960920101001	upadacitinib [Rinvoq]	\$1,239,236
10	R22569510301001	elexacaftor ivacaftor tezacaftor [Trikafta]	\$1,082,784
11	R15512910101001	dulaglutide [Trulicity]	\$900,231
12	R15997880101001	secukinumab [Cosentyx]	\$869,542
13	R03423690101000	lenalidomide	\$864,512
14	R19897940101001	emicizumab [Hemlibra]	\$808,270
15	R11481380101000	icatibant	\$767,938
16	R13644300101001	apixaban [Eliquis]	\$759,972
17	R16013740101001	palbociclib [Ibrance]	\$730,601
18	R02762370201001	emtricitabine tenofovir alafenamide [Descovy]	\$705,528
19	R12429990101001	axitinib [Inlyta]	\$667,459
20	R16032960101001	lenvatinib [Lenvima]	\$664,012
21	R03582570101001	tolvaptan [Jynarque]	\$647,485
22	R17215600101001	osimertinib [Tagrisso]	\$643,192
23	R19468250101001	abemaciclib [Verzenio]	\$640,737
24	R20463600101001	pegvaliase [Palynziq]	\$621,800
25	R18739160101001	ribociclib [Kisqali]	\$596,341

Small Group Market - Summary Prescription Drug Costs Reporting - Part 4 Inquiry and Response Items		
Question:	Range	
On average, what portion (on both a percentage and dollar PMPM basis) of your plan year 2025 premium rates is associated with covering expected prescription drug claims?	9.80% to 19.30% \$61.06 to \$128.00 PMPM	
	Number of Carriers Responding "Yes"	Number of Carriers Responding "No"
Do any health plans offered by the health carrier require enrollees to pay cost-sharing on any covered prescription drugs including deductibles, co-payments, or coinsurance in an amount that is greater than the amount the enrollee's health plan would pay for the drug absent the applicable enrollee cost-sharing and after accounting for any rebate amount?	5	3
	Number of Carriers Responding "Yes"	Number of Carriers Responding "No"
Does the health carrier prohibit third-party payments including manufacturer drug discounts or coupons that cover all or a portion of an enrollee's cost-sharing requirements including deductibles, co-payments, or coinsurance from applying toward the enrollee's cost-sharing obligations under the enrollee's health plan?	0	8

Individual Market - Summary Prescription Drug Costs Reporting - Part 1

Top 25 Most Frequently Prescribed Drugs in Plan Year 2023

Rank	Drug Code (RxDC)	Drug Name	Total Number of Prescriptions
1	R00004350101004	albuterol [Ventolin]	9,748
2	R00007250201001	amphetamine dextroamphetamine [Adderall]	7,409
3	R19913020101001	semaglutide [Ozempic]	6,385
4	R15512910101001	dulaglutide [Trulicity]	5,662
5	R13644300101001	apixaban [Eliquis]	5,204
6	70461032303	FLUCELVAX QUAD 2023-2024	4,467
7	R03273610101001	adalimumab [Humira]	3,995
8	R15456530101001	empagliflozin [Jardiance]	3,644
9	R07008100101001	lisdexamfetamine [Vyvanse]	3,631
10	R19868210101001	varicella zoster virus glycoprotein E [Shingrix]	2,788
11	R00105820101005	levothyroxine [Synthroid]	2,736
12	R00411260201001	fluticasone salmeterol [Advair]	2,668
13	58160090952	FLUARIX QUAD 2023-2024	2,603
14	R25878920201002	nirmatrelvir ritonavir [Paxlovid 5-Day]	2,521
15	R19996600302001	bictegravir emtricitabine tenofovir alafenamide [Biktarvy]	2,485
16	80777010293	SPIKEVAX 2023-2024	2,308
17	R00514280101002	insulin aspart human [NovoLog]	2,247
18	69236210	COMIRNATY 2023-2024	2,190
19	69239210	COMIRNATY 2023-2024	2,108
20	R11141950101001	rivaroxaban [Xarelto]	2,013
21	R02747830101001	insulin glargine [Basaglar]	1,884
22	49281042350	FLUZONE QUAD 2023-2024	1,870
23	R26017230101001	tirzepatide [Mounjaro]	1,819
24	R02747830101002	insulin glargine [Lantus]	1,707
25	R00411260101005	fluticasone [Flovent]	1,533

Individual Market - Summary Prescription Drug Costs Reporting - Part 2

**Most Costly Prescription Drugs as a Portion of
Total Annual Expenditures in Plan Year 2023**

Rank	Drug Code (RxDC)	Drug Name	Aggregate Annual Cost of Drug
1	R03273610101001	adalimumab [Humira]	\$19,086,405
2	R19996600302001	bictegravir emtricitabine tenofovir alafenamide [Biktarvy]	\$10,120,585
3	R08470830101001	ustekinumab [Stelara]	\$7,712,488
4	R22569510301001	elexacaftor ivacaftor tezacaftor [Trikafta]	\$6,062,661
5	R21660400101001	risankizumab [Skyrizi]	\$5,197,786
6	R02145550101001	etanercept [Enbrel]	\$5,163,139
7	R19913020101001	semaglutide [Ozempic]	\$4,157,031
8	R15512910101001	dulaglutide [Trulicity]	\$4,074,546
9	R13644300101001	apixaban [Eliquis]	\$3,424,624
10	R18763760101001	dupilumab [Dupixent]	\$3,056,612
11	R19468250101001	abemaciclib [Verzenio]	\$2,863,395
12	R02762370201001	emtricitabine tenofovir alafenamide [Descovy]	\$2,703,449
13	R03423690101001	lenalidomide [Revlimid]	\$2,586,048
14	R15997880101001	secukinumab [Cosentyx]	\$2,298,048
15	R13062840402001	cobicistat elvitegravir emtricitabine tenofovir alafenamide [Genvoya]	\$1,770,782
16	R21960920101001	upadacitinib [Rinvoq]	\$1,687,688
17	R15456530101001	empagliflozin [Jardiance]	\$1,674,776
18	R19285880101001	guselkumab [Tremfya]	\$1,560,999
19	R00058820101001	interferon gamma-1b [Actimmune]	\$1,498,657
20	R26017230101001	tirzepatide [Mounjaro]	\$1,446,445
21	R14429810101001	ibrutinib [Imbruvica]	\$1,413,108
22	R11141950101001	rivaroxaban [Xarelto]	\$1,388,943
23	R16032960101001	lenvatinib [Lenvima]	\$1,328,900
24	R02762370301001	emtricitabine rilpivirine tenofovir alafenamide [Odefsey]	\$1,266,634
25	R19897940101001	emicizumab [Hemlibra]	\$1,173,663

Individual Market - Summary Prescription Drug Costs Reporting - Part 3

**Prescription Drugs that have Caused the
Greatest Increase in Total Spending in Plan Year 2023**

Rank	Drug Code (RxDC)	Drug Name	Aggregate Increase in Annual Spending
1	R03273610101001	adalimumab [Humira]	\$6,176,113
2	R21660400101001	risankizumab [Skyrizi]	\$3,290,554
3	R19913020101001	semaglutide [Ozempic]	\$3,125,480
4	R08470830101001	ustekinumab [Stelara]	\$3,003,206
5	R22569510301001	elexacaftor ivacaftor tezacaftor [Trikafta]	\$2,290,341
6	R19996600302001	bictegravir emtricitabine tenofovir alafenamide [Biktarvy]	\$2,273,012
7	R02145550101001	etanercept [Enbrel]	\$2,184,646
8	R19468250101001	abemaciclib [Verzenio]	\$1,709,298
9	R15997880101001	secukinumab [Cosentyx]	\$1,570,906
10	R15512910101001	dulaglutide [Trulicity]	\$1,545,251
11	R13644300101001	apixaban [Eliquis]	\$1,483,222
12	R18763760101001	dupilumab [Dupixent]	\$1,269,130
13	R21960920101001	upadacitinib [Rinvoq]	\$1,246,017
14	R19913020101003	semaglutide [Wegovy]	\$1,085,926
15	R15456530101001	empagliflozin [Jardiance]	\$1,049,524
16	R16032960101001	lenvatinib [Lenvima]	\$989,313
17	R02762370202000	emtricitabine tenofovir disoproxil	\$889,004
18	R18739160101001	ribociclib [Kisqali]	\$835,361
19	R00058820101001	interferon gamma-1b [Actimmune]	\$799,781
20	R03423690101000	lenalidomide	\$778,963
21	R17202590101001	asfotase alfa [Strensiq]	\$757,191
22	R19285880101001	guselkumab [Tremfya]	\$664,662
23	R02762370201001	emtricitabine tenofovir alafenamide [Descovy]	\$641,010
24	R03582570101001	tolvaptan [Jynarque]	\$636,848
25	R14429810101001	ibrutinib [Imbruvica]	\$586,489

Individual Market - Summary Prescription Drug Costs Reporting - Part 4
Inquiry and Response Items

Question:	Range	
On average, what portion (on both a percentage and dollar PMPM basis) of your plan year 2025 premium rates is associated with covering expected prescription drug claims?	14.48% to 23.30% \$45.22 to \$125.65 PMPM	
	Number of Carriers Responding "Yes"	Number of Carriers Responding "No"
Do any health plans offered by the health carrier require enrollees to pay cost-sharing on any covered prescription drugs including deductibles, co-payments, or coinsurance in an amount that is greater than the amount the enrollee's health plan would pay for the drug absent the applicable enrollee cost-sharing and after accounting for any rebate amount?	5	0
	Number of Carriers Responding "Yes"	Number of Carriers Responding "No"
Does the health carrier prohibit third-party payments including manufacturer drug discounts or coupons that cover all or a portion of an enrollee's cost-sharing requirements including deductibles, co-payments, or coinsurance from applying toward the enrollee's cost-sharing obligations under the enrollee's health plan?	0	5

Prescription Drug Data Collection Templates

D3 Top 50 Most Freq Brand Drugs

[illegible]

D4 Top 50 Most Costly Drugs

[illegible]

D5 Top 50 Drugs by Spending Increase

Issuer or TPA Name	Issuer or TPA EIN	State	Market Segment	Drug Name	Drug Code	Spending Increase Rank	Number of Paid Claims	Number of Members with a Paid Claim	Number of Dosage Units	Total Spending	Total Cost Sharing	Manufacturer Cost-Sharing Assistance

Prior Year Number of Paid Claims	Prior Year Number of Members with a Paid Claim	Prior Year Number of Dosage Units	Prior Year Total Spending	Prior Year Total Cost Sharing	Prior Year Manufacturer Cost-Sharing Assistance	Dollar Increase in Total Spending

Prescription Drug Cost Supplemental Form

Issuer Name:

Market:

SERFF Tracking Number:

Plan Year:

This template is required for all issuers in the Individual and Small Group Markets.

1. On average, what portion (on both a percentage and dollar PMPM basis) of your plan year 2025 premium rates is associated with covering expected prescription drug claims?

2. Do any health plans offered by the health carrier require enrollees to pay cost-sharing on any covered prescription drugs including deductibles, co-payments, or coinsurance in an amount that is greater than the amount the enrollee's health plan would pay for the drug absent the applicable enrollee cost-sharing and after accounting for any rebate amount?

☐

Yes

☐

No

3. Does the health carrier prohibit third-party payments including manufacturer drug discounts or coupons that cover all or a portion of an enrollee's cost-sharing requirements including deductibles, co-payments, or coinsurance from applying toward the enrollee's cost-sharing obligations under the enrollee's health plan?

☐ Yes ☐ No